Redefining the. Management of. The 2015 Canadian Guidelines: the. Uterine Fibroids- The Future. A Focus on Fibristal
|
|
- Conrad Harris
- 5 years ago
- Views:
Transcription
1 The 2015 Canadian Guidelines: the Redefining the Management of Uterine Fibroids- The Future A Focus on Fibristal ulipristal acetate TM Nicholas A. Leyland, BASc, MD, MHCM, FRCSC Professor and Chair Department of Obstetrics and Gynaecology Faculty of Health Sciences Michael A Symposium G. for DeGroote Canadian Obstetricians/Gynecologists School of Medicine McMaster University
2 Learning Objectives! Review the summary statements and the recommendations from the recently published Society of Obstetricians and Gynaecologists of Canada clinical practice guidelines! Review the various options for the management of uterine fibroids depending on the presenting symptoms and the patient s desire for fertility preservation.
3 MARCH JOGC MARS SOGC CLINICAL PRACTICE GUIDELINE SOGC CLINICAL PRACTICE GUIDELINE SOGC/GOC TECHNICAL UPDATE No. 318, February 2015 (Replaces, No. 128, May 2003) The Management of Uterine Leiomyomas Outcomes: Implementation of this guideline should optimize This clinical practice guideline has been prepared by the the decision-making process of women and their health care providers in proceeding with further investigation or therapy for Clinical Practice Gynaecology, Reproductive Endocrinology uterine leiomyomas, having considered the disease process & Infertility, and Family Physician Advisory Committees, and available treatment options, and reviewed the risks and and approved by the Executive and Board of the Society of Obstetricians and Gynaecologists of Canada. Evidence: Published literature was retrieved through searches of PubMed, CINAHL, and Cochrane Systematic Reviews in PRINCIPAL AUTHORS February 2013, using appropriate controlled vocabulary (uterine George A. Vilos, MD, London ON menstrual bleeding, and menorrhagia) and key words (myoma, Catherine Allaire, MD, Vancouver BC Philippe-Yves Laberge, MD, Quebec QC hysterectomy, heavy menstrual bleeding, menorrhagia). The Nicholas Leyland, MD, MHCM, Hamilton ON relevant publications. Results were restricted to systematic SPECIAL CONTRIBUTORS reviews, randomized control trials/controlled clinical trials, and observational studies. There were no date limits but results were Angelos G. Vilos, MD, London, ON limited to English or French language materials. Searches were Ally Murji, MD, MPH, Toronto, ON updated on a regular basis and incorporated in the guideline Innie Chen, MD, Ottawa, ON through searching the websites of health technology assessment Disclosure statements have been received from all contributors. and health technology related agencies, clinical practice guideline collections, and national and international medical The literature searches and bibliographic support for this specialty societies. guideline were undertaken by Becky Skidmore, Medical Reserch Analyst, Society of Obstetricians and Gynaecologists of Canada. asymptomatic and require no intervention or further menstrual abnormalities (e.g. heavy, irregular, and prolonged Abstract (e.g., pelvic pressure/pain, obstructive symptoms), hysterectomy Objectives: The aim of this guideline is to provide clinicians with an for women who wish to preserve fertility and/or their uterus. The understanding of the pathophysiology, prevalence, and clinical selected treatment should be directed towards an improvement in symptomatology and quality of life. The cost of the therapy treatment modalities. be interpreted in the context of the cost of untreated disease Options: The areas of clinical practice considered in formulating this conditions and the cost of ongoing or repeat investigative or guideline were assessment, medical treatments, conservative treatment modalities. treatments of myolysis, selective uterine artery occlusion, and surgical alternatives including myomectomy and hysterectomy. Values: The quality of evidence in this document was rated using the criteria described in the Report of the Ca adian Task Force woman and her health care provider. on Preventive Health Care (Table 1). Key Words: artery embolization, hysterectomy, heavy menstrual bleeding, menorrhagia J Obstet Gynaecol Can 2015;37(2): No. 321, March 2015 The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility This clinical practice guideline was prepared by the Reproductive Endocrinology and Infertility Committee, reviewed by Family Physician Advisory and Clinical Practice Gynaecology Committees, and approved by the Executive and Board of the Society of Obstetricians and Gynaecologists of Canada. PRINCIPAL AUTHORS Belina Carranza-Mamane, MD, Sherbrooke QC Jon Havelock, MD, Vancouver BC Robert Hemmings, MD, Montreal QC REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY COMMITTEE Anthony Cheung (Co-chair), MD, Vancouver BC Sony Sierra (Co-chair), MD, Toronto ON Belina Carranza-Mamane, MD, Sherbrooke QC Allison Case, MD, Saskatoon SK Cathie Dwyer, RN, Toronto ON James Graham, MD, Calgary AB Jon Havelock, MD, Vancouver BC Robert Hemmings, MD, Montreal QC Kimberly Liu, MD, Toronto ON Ward Murdock, MD, Fredericton NB Tannys Vause, MD, Ottawa ON Benjamin Wong, MD, Calgary AB SPECIAL CONTRIBUTOR Margaret Burnett, MD, Winnipeg MB Disclosure statements have been received from all contributors. Keywords: Female leiomyoma, myomectomy, uterine artery embolization, in vitro fertilization, ovarian reserve, ulipristal acetate, magnetic resonance-guided focused ultrasound surgery. Abstract Objective: To provide recommendations regarding the best with emphasis on their applicability in women who wish to conceive. Options: surgical, but must be weighed against the evidence of surgical surgical management and approach. Outcomes: The outcomes of primary concern are the improvement women with infertility. Evidence: Published literature was retrieved through searches of PubMed, MEDLINE, the Cochrane Library in November 2013 using appropriate controlled vocabulary (e.g., leiomyoma, infertility, uterine artery embolization, fertilization in vitro) and key systematic reviews, randomized control trials/controlled clinical trials, and observational studies published in English and French. There were no date restrictions. Searches were updated on a regular basis and incorporated in the guideline to November websites of health technology assessment and health technologyrelated agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies. Values: The quality of evidence in this document was rated using the criteria described by the Canadian Task Force on Preventive Health Care (Table). : These recommendations are expected infertility, maximizing their chances of pregnancy by minimizing risks introduced by unnecessary myomectomies. Reducing complications and eliminating unnecessary interventions are also expected to decrease costs to the health care system. J Obstet Gynaecol Can 2015;37(3): Technical Update on Tissue Morcellation During Gynaecologic Surgery: Its Uses, Complications, and Risks of Unsuspected Malignancy This technical update has been prepared by the Clinical Practice Gynaecology Committee of the Society of Obstetricians and Gynaecologists of Canada (SOGC) and the Executive of the Society of Gynecologic Oncology of Canada (GOC) and approved by the Executive and Board of the SOGC and the Board of Directors of the GOC. PRINCIPAL AUTHORS Sukhbir S. Singh, MD, Ottawa ON Stephanie Scott, MD, Vancouver BC Olga Bougie, MD, Ottawa ON Nicholas Leyland, MD, Hamilton ON SOGC CLINICAL PRACTICE GYNAECOLOGY COMMITTEE Nicholas Leyland, MD (Co-chair), Hamilton ON Wendy Wolfman, MD (Co-chair), Toronto ON Catherine Allaire, MD, Vancouver BC Alaa Awadalla, MD, Winnipeg MB Annette Bullen, RN, Caledonia ON Margaret Burnett, MD, Winnipeg MB Susan Goldstein, MD, Toronto ON Madeleine Lemyre, MD, Quebec QC Violaine Marcoux, MD, Montreal QC Frank Potestio, MD, Thunder Bay ON David Rittenberg, MD, Halifax NS Sukhbir S. Singh, MD, Ottawa ON Grace Yeung, MD, London ON GOC EXECUTIVE COMMITTEE Paul Hoskins, MD, Vancouver BC Dianne Miller, MD, Vancouver BC Walter Gotlieb, MD, Montreal QC Marcus Bernardini, MD, Toronto ON SPECIAL CONTRIBUTOR Laura Hopkins, MD, Ottawa ON Disclosure statements have been received from all contributors. Abstract Objective: To review the use of tissue morcellation in minimally invasive gynaecological surgery. Outcomes: Morcellation may be used in gynaecological surgery to allow removal of large uterine specimens, providing women with a minimally invasive surgical option. Adverse oncologic outcomes of tissue morcellation should be mitigated through improved patient selection, preoperative investigations, and novel techniques that minimize tissue dispersion. Evidence: Published literature was retrieved through searches of PubMed and Medline in the spring of 2014 using appropriate controlled vocabulary (leiomyomsarcoma, uterine neoplasm, uterine myomectomy, hysterectomy) and key words (leiomyoma, endometrial cancer, uterine sarcoma, leiomyosarcoma, morcellation, and MRI). Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. There were no date limits but results were limited to English or French language materials. Searches were updated on a regular basis and incorporated in the guideline to August Grey (unpublished) literature technology assessment and health technology assessmentrelated agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies. Values: The quality of evidence in this document was rated using the criteria described in the report of the Canadian Task Force on Preventive Health Care. (Table 1) Gynaecologists may offer women minimally invasive surgery and this may involve tissue morcellation and the use of a power morcellator for specimen retrieval. Women should be counselled that in the case of Key Words: leiomyoma, uterine sarcoma, leiomyosarcoma, morcellation, complications J Obstet Gynaecol Can 2015;37(1):68 78 This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions. They should be well documented if modified at the local level. None of these contents may be reproduced in any form without prior written permission of the SOGC. This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions. They should be well documented if modified at the local level. None of these contents may be reproduced in any form without prior written permission of the SOGC. FEBRUARY JOGC FÉVRIER JANUARY JOGC JANVIER 2015
4 Key to evidence statements and grading of recommendations, using the ranking of the Canadian Task Force on Preventive Health Care Quality of evidence assessment* I: Evidence obtained from at least one properly randomized controlled trial II-1: Evidence from well-designed controlled trials without randomization II-2: Evidence from well-designed cohort (prospective or retrospective) or case control studies, preferably from more than one centre or research group A. There is good evidence to recommend the clinical preventive action B. There is fair evidence to recommend the clinical preventive action C. recommendation for or against use of the clinical preventive action; II-3: Evidence obtained from comparisons between times or places with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of treatment with penicillin in the 1940s) could also be included in this category D. There is fair evidence to recommend against the clinical preventive action E. There is good evidence to recommend against the clinical preventive action III: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees decision-making *The quality of evidence reported in here has been adapted from The Evaluation of Evidence criteria described in the Canadian Task Force on Preventive Health Care. 52 on Preventive Health Care. 52
5 Diagnosis of Uterine Fibroids! Clinical history! presentation " Pain (degeneration) " Bulk " Menorrhagia (SOGC 2013)! Determine impact on patient s quality of life! Physical exam,! Appropriate imaging! Remember contiguous structures- R/O Hydronephrosis Khan AT, et al. Int J Womens Health 2014;6:95-114
6 FIGO Classification System 12 Leiomyoma Subclassification System S Submusosal 0 Pedunculated intracavitary 1 < 50% intramural O Other 3 Contacts endometrium; 100% intramural 4 Intramural 6 Subserosal < 50% intramural 7 Subserosal pedunculated 8 Other (specify e.g. cervical, parasitic) Hybrid leiomyomas (impact both endometrium and serosa) Two numbers are listed separated by a hyphen. By convention, the first refers to the relationship with the endometrium while the second refers to the relationship to the serosa. One example is below 2-5 Submusocal and subserosal, each with less than half the diameter in the endometrial and peritoneal cavities, respectively.
7 Classification of Fibroids-Clinical European Society of Hysteroscopy Classification: 1 TYPE 0 Intracavitary TYPE I > 50% in cavity TYPE II < 50% in cavity TYPE III Serosal/intramural Myoma to serosa distance *Endometrium coverage 1. Wamsteker K, et al. Obstet Gynecol 1993;82: Munro MG, et al. Int J Gynaecol Obstet 2011;113:3-13
8 1.. Singh, S., et al. J Obstet Gynaecol Can 2013;35(5 esuppl):s1-s28 2. Singh, Scott, Bougie, Leyland, et al. J Obstet Gynaecol Can 2015;25: ; 2. Brooks SE, et al. Gynecol Oncol 2004;93:204-8; 3. Seidman MA, et al. PLoS One 2012;7:e50058 Diagnostic Work-up! Investigate based on presentation " Abnormal uterine bleeding # Blood work-up (hemoglobin, ferritin) # Endometrial biopsy as per guidelines to rule out pathology! Uterine stromal tumours are rare (1 in 352) 2 # Incidence may be higher in patients undergoing surgery 3 # No diagnostic test determines sarcoma (1 in 500 to 1 in 1000)
9 Diagnostic Work-up (cont d)! Imaging is important to determine location & rule out other pathology- Fibroid Mapping! Pelvic ultrasound: Endovaginal and/or transabdominal! Contrast (gel, saline) infusion sonography- Virtual Hysteroscopy! MRI: Allows determination of location, size, number, and perfusion of fibroids! Hysteroscopy MRI = Magnetic resonance imaging 1. Khan AT, et al. Int J Womens Health 2014;6: Singh, S., et al. J Obstet Gynaecol Can 2013;35(5 esuppl):s1-s28
10 Brölmann H, et al. Internet J Gynecol Obstetrics 2007; /1/6739 Treatment Approaches for Uterine Fibroids! Medical! Surgical! Interventional Uterine artery embolization MRI-guided focused ultrasound
11 Figure 2. Algorithm for the management of uterine myomas Uterine myomas Asymptomatic Symptomatic Clinical surveillance Pre-menopause Post-menopause Enhance fertility Retain fertility Retain uterus Other f Investigations: - Endometrial biopsy - Imaging - Hysteroscopy See SOGC Guideline 19 AUB Medical therapy: - SPRM (Ulipristal) - OC - Danazol - LNG-IUS - Tranexamic acid - GnRH agonist ± add-back Bulk effects ± AUB Medical therapy: - SPRM (Ulipristal) - GnRH-agonist ± add-back Bulk effects ± AUB Interventional therapy: - UAE - MRg-FUS - Myolysis Hysterectomy ± BSO Hysteroscopic myomectomy Surgical therapy: Myomectomy - Hysteroscopic - Laparoscopic - Laparotomic Surgical therapy Myomectomy - Hysteroscopic - Laparoscopic - Laparotomic Surgical therapy: Myomectomy ± EA - Hysteroscopic - Laparoscopic - Laparotomic BSO: bilateral salpingo-oophorectomy; MRg-FUS: Magnetic resonance-guided focused ultrasound; OC: oral contraceptives
12 SOGC CLINICAL PRACTICE GUIDELINE No. 318, February 2015 (Replaces, No. 128, May 2003) The Management of Uterine Leiomyomas This clinical practice guideline has been prepared by the Clinical Practice Gynaecology, Reproductive Endocrinology & Infertility, and Family Physician Advisory Committees, and approved by the Executive and Board of the Society of Obstetricians and Gynaecologists of Canada. PRINCIPAL AUTHORS George A. Vilos, MD, London ON Catherine Allaire, MD, Vancouver BC Philippe-Yves Laberge, MD, Quebec QC Nicholas Leyland, MD, MHCM, Hamilton ON SPECIAL CONTRIBUTORS Angelos G. Vilos, MD, London, ON Ally Murji, MD, MPH, Toronto, ON Innie Chen, MD, Ottawa, ON Disclosure statements have been received from all contributors. The literature searches and bibliographic support for this guideline were undertaken by Becky Skidmore, Medical Reserch Analyst, Society of Obstetricians and Gynaecologists of Canada. Abstract Objectives: The aim of this guideline is to provide clinicians with an understanding of the pathophysiology, prevalence, and clinical treatment modalities. Options: The areas of clinical practice considered in formulating this guideline were assessment, medical treatments, conservative treatments of myolysis, selective uterine artery occlusion, and surgical alternatives including myomectomy and hysterectomy. woman and her health care provider. Outcomes: Implementation of this guideline should optimize the decision-making process of women and their health care providers in proceeding with further investigation or therapy for uterine leiomyomas, having considered the disease process and available treatment options, and reviewed the risks and Evidence: Published literature was retrieved through searches of PubMed, CINAHL, and Cochrane Systematic Reviews in February 2013, using appropriate controlled vocabulary (uterine menstrual bleeding, and menorrhagia) and key words (myoma, hysterectomy, heavy menstrual bleeding, menorrhagia). The relevant publications. Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. There were no date limits but results were limited to English or French language materials. Searches were updated on a regular basis and incorporated in the guideline through searching the websites of health technology assessment and health technology related agencies, clinical practice guideline collections, and national and international medical specialty societies. asymptomatic and require no intervention or further menstrual abnormalities (e.g. heavy, irregular, and prolonged (e.g., pelvic pressure/pain, obstructive symptoms), hysterectomy for women who wish to preserve fertility and/or their uterus. The selected treatment should be directed towards an improvement in symptomatology and quality of life. The cost of the therapy be interpreted in the context of the cost of untreated disease conditions and the cost of ongoing or repeat investigative or treatment modalities. Values: The quality of evidence in this document was rated using the criteria described in the Report of the Ca adian Task Force on Preventive Health Care (Table 1). Key Words: artery embolization, hysterectomy, heavy menstrual bleeding, menorrhagia J Obstet Gynaecol Can 2015;37(2): This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information FEBRUARY JOGC FÉVRIER
13 SOGC CLINICAL PRACTICE GUIDELINE No. 318, February 2015 (Replaces, No. 128, May 2003) Recommendations The Management of Uterine Leiomyomas there is no evidence to substantiate major concern about malignancy and that hysterectomy is not indicated. (III-D) 2. Treatment of women with uterine leiomyomas must be individualized based on symptomatology, size and location of or the uterus, the availability of therapy, and the experience of the therapist. (III-B) 3. In women who do not wish to preserve fertility and/or their uterus and who have been counselled regarding the alternatives and risks, hysterectomy by the least invasive approach possible may
14 SOGC CLINICAL PRACTICE GUIDELINE No. 318, February 2015 (Replaces, No. 128, May 2003) The Management of Uterine Leiomyomas line conservative surgical therapy for the management of 5. Surgical planning for myomectomy should be based on mapping appropriate imaging. (III-A) 6. When morcellation is necessary to remove the specimen, the patient should be informed about possible risks and contain unexpected malignancy and that laparoscopic power morcellation may spread the cancer, potentially worsening their prognosis. (III-B) 7. Anemia should be corrected prior to proceeding with elective
15 SOGC CLINICAL PRACTICE GUIDELINE No. 318, February 2015 (Replaces, No. 128, May 2003) The Management of Uterine Leiomyomas line conservative surgical therapy for the management of 5. Surgical planning for myomectomy should be based on mapping appropriate imaging. (III-A) 6. When morcellation is necessary to remove the specimen, the patient should be informed about possible risks and contain unexpected malignancy and that laparoscopic power morcellation may spread the cancer, potentially worsening their prognosis. (III-B) 7. Anemia should be corrected prior to proceeding with elective
16 SOGC CLINICAL PRACTICE GUIDELINE No. 318, February 2015 (Replaces, No. 128, May 2003) The Management of Uterine Leiomyomas 7. Anemia should be corrected prior to proceeding with elective surgery. (II-2A) Selective progesterone receptor modulators and gonadotropin-releasing hormone analogues are effective at correcting anemia and should be considered preoperatively in anemic patients. (I-A) 8. Use of vasopressin, bupivacaine and epinephrine, misoprostol, peri-cervical tourniquet, or gelatin-thrombin matrix reduce blood loss at myomectomy and should be considered. (I-A) 9. Uterine artery occlusion by embolization or surgical methods may be offered to selected women with symptomatic uterine counselled regarding possible risks, including the likelihood that fecundity and pregnancy may be impacted. (II-3A)
17 SOGC CLINICAL PRACTICE GUIDELINE No. 318, February 2015 (Replaces, No. 128, May 2003) The Management of Uterine Leiomyomas 10. In women who present with acute uterine bleeding associated Foley catheter tamponade, and/or operative hysteroscopic intervention may be considered, but hysterectomy may become necessary in some cases. In centres where available, intervention by uterine artery embolization may be considered. (III-B)
18 SOGC CLINICAL PRACTICE GUIDELINE No. 318, February 2015 (Replaces, No. 128, May 2003) The Management of Uterine Leiomyomas Summary Statements age 50; the 20% to 50% that are symptomatic have considerable social and economic impact in Canada. (II-3) challenges. (III) pregnancy is not an indication for myomectomy except in women who have had a previous pregnancy with complications related additional maternal and fetal surveillance. (II-2)
19 SOGC CLINICAL PRACTICE GUIDELINE No. 318, February 2015 (Replaces, No. 128, May 2003) The Management of Uterine Leiomyomas 5. Effective medical treatments for women with abnormal uterine intrauterine system, (I) gonadotropin-releasing hormone analogues, (I) selective progesterone receptor modulators, (I) oral contraceptives, (II-2) progestins, (II-2) and danazol. (II-2) 6. Effective medical treatments for women with bulk symptoms modulators and gonadotropin-releasing hormone analogues. (I) 7. Hysterectomy is the most effective treatment for symptomatic
20 SOGC CLINICAL PRACTICE GUIDELINE No. 318, February 2015 (Replaces, No. 128, May 2003) The Management of Uterine Leiomyomas 8. Myomectomy is an option for women who wish to preserve their uterus or enhance fertility, but carries the potential for further intervention. (II-2) 9. Of the conservative interventional treatments currently available, uterine artery embolization has the longest track record and has been shown to be effective in properly selected patients. (II-3) 10. Newer focused energy delivery methods are promising but lack long-term data. (III)
21 SOGC CLINICAL PRACTICE GUIDELINE No. 321, March 2015 The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility This clinical practice guideline was prepared by the Reproductive Endocrinology and Infertility Committee, reviewed by Family Physician Advisory and Clinical Practice Gynaecology Committees, and approved by the Executive and Board of the Society of Obstetricians and Gynaecologists of Canada. PRINCIPAL AUTHORS Belina Carranza-Mamane, MD, Sherbrooke QC Jon Havelock, MD, Vancouver BC Robert Hemmings, MD, Montreal QC REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY COMMITTEE Anthony Cheung (Co-chair), MD, Vancouver BC Sony Sierra (Co-chair), MD, Toronto ON Belina Carranza-Mamane, MD, Sherbrooke QC Allison Case, MD, Saskatoon SK Cathie Dwyer, RN, Toronto ON James Graham, MD, Calgary AB Jon Havelock, MD, Vancouver BC Robert Hemmings, MD, Montreal QC Kimberly Liu, MD, Toronto ON Ward Murdock, MD, Fredericton NB Tannys Vause, MD, Ottawa ON Benjamin Wong, MD, Calgary AB SPECIAL CONTRIBUTOR Margaret Burnett, MD, Winnipeg MB Disclosure statements have been received from all contributors. Keywords: Female leiomyoma, myomectomy, uterine artery embolization, in vitro fertilization, ovarian reserve, ulipristal acetate, magnetic resonance-guided focused ultrasound surgery. Abstract Objective: To provide recommendations regarding the best with emphasis on their applicability in women who wish to conceive. Options: surgical, but must be weighed against the evidence of surgical surgical management and approach. Outcomes: The outcomes of primary concern are the improvement women with infertility. Evidence: Published literature was retrieved through searches of PubMed, MEDLINE, the Cochrane Library in November 2013 using appropriate controlled vocabulary (e.g., leiomyoma, infertility, uterine artery embolization, fertilization in vitro) and key systematic reviews, randomized control trials/controlled clinical trials, and observational studies published in English and French. There were no date restrictions. Searches were updated on a regular basis and incorporated in the guideline to November websites of health technology assessment and health technologyrelated agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies. Values: The quality of evidence in this document was rated using the criteria described by the Canadian Task Force on Preventive Health Care (Table). : These recommendations are expected infertility, maximizing their chances of pregnancy by minimizing risks introduced by unnecessary myomectomies. Reducing complications and eliminating unnecessary interventions are also expected to decrease costs to the health care system. J Obstet Gynaecol Can 2015;37(3): This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions. They should be well documented if modified at the local level. None of these contents may be reproduced in any form without prior written permission of the SOGC. MARCH JOGC MARS
22 SOGC CLINICAL PRACTICE GUIDELINE No. 321, March 2015 The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility Recommendations 1. In women with infertility, an effort should be made to adequately endometrial cavity, using transvaginal ultrasound, hysteroscopy, hysterosonography, or magnetic resonance imaging. (III-A) uterine cavity, evaluation of the degree of invasion of the cavity and thickness of residual myometrium to the serosa. A combination of hysteroscopy and transvaginal ultrasound or hysterosonography are the modalities of choice. (III-B) managed hysteroscopically, but repeat procedures are often necessary. (III-B)
23 SOGC CLINICAL PRACTICE GUIDELINE No. 321, March 2015 The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility 4. A hysterosalpingogram is not an appropriate exam to evaluate and 5. In women with otherwise unexplained infertility, submucosal pregnancy rates. (II-2A)
24 SOGC CLINICAL PRACTICE GUIDELINE No. 321, March 2015 The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility 7. There is fair evidence to recommend against myomectomy in endometrium) and otherwise unexplained infertility, regardless of of myomectomy should be weighed against the risks, and
25 SOGC CLINICAL PRACTICE GUIDELINE No. 321, March 2015 The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility to use an anterior uterine incision to minimize the formation of postoperative adhesions. (II-2A) 9. Widespread use of the laparoscopic approach to myomectomy selection should be individualized based on the number, size, and 10. Women, fertile or infertile, seeking future pregnancy should not generally be offered uterine artery embolization as a treatment
26 SOGC/GOC TECHNICAL UPDATE Technical Update on Tissue Morcellation During Gynaecologic Surgery: Its Uses, Complications, and Risks of Unsuspected Malignancy This technical update has been prepared by the Clinical Practice Gynaecology Committee of the Society of Obstetricians and Gynaecologists of Canada (SOGC) and the Executive of the Society of Gynecologic Oncology of Canada (GOC) and approved by the Executive and Board of the SOGC and the Board of Directors of the GOC. PRINCIPAL AUTHORS Sukhbir S. Singh, MD, Ottawa ON Stephanie Scott, MD, Vancouver BC Olga Bougie, MD, Ottawa ON Nicholas Leyland, MD, Hamilton ON SOGC CLINICAL PRACTICE GYNAECOLOGY COMMITTEE Nicholas Leyland, MD (Co-chair), Hamilton ON Wendy Wolfman, MD (Co-chair), Toronto ON Catherine Allaire, MD, Vancouver BC Alaa Awadalla, MD, Winnipeg MB Annette Bullen, RN, Caledonia ON Margaret Burnett, MD, Winnipeg MB Susan Goldstein, MD, Toronto ON Madeleine Lemyre, MD, Quebec QC Violaine Marcoux, MD, Montreal QC Frank Potestio, MD, Thunder Bay ON David Rittenberg, MD, Halifax NS Sukhbir S. Singh, MD, Ottawa ON Grace Yeung, MD, London ON GOC EXECUTIVE COMMITTEE Paul Hoskins, MD, Vancouver BC Dianne Miller, MD, Vancouver BC Walter Gotlieb, MD, Montreal QC Marcus Bernardini, MD, Toronto ON SPECIAL CONTRIBUTOR Laura Hopkins, MD, Ottawa ON Disclosure statements have been received from all contributors. Abstract Objective: To review the use of tissue morcellation in minimally invasive gynaecological surgery. Outcomes: Morcellation may be used in gynaecological surgery to allow removal of large uterine specimens, providing women with a minimally invasive surgical option. Adverse oncologic outcomes of tissue morcellation should be mitigated through improved patient selection, preoperative investigations, and novel techniques that minimize tissue dispersion. Evidence: Published literature was retrieved through searches of PubMed and Medline in the spring of 2014 using appropriate controlled vocabulary (leiomyomsarcoma, uterine neoplasm, uterine myomectomy, hysterectomy) and key words (leiomyoma, endometrial cancer, uterine sarcoma, leiomyosarcoma, morcellation, and MRI). Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. There were no date limits but results were limited to English or French language materials. Searches were updated on a regular basis and incorporated in the guideline to August Grey (unpublished) literature technology assessment and health technology assessmentrelated agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies. Values: The quality of evidence in this document was rated using the criteria described in the report of the Canadian Task Force on Preventive Health Care. (Table 1) Gynaecologists may offer women minimally invasive surgery and this may involve tissue morcellation and the use of a power morcellator for specimen retrieval. Women should be counselled that in the case of Key Words: leiomyoma, uterine sarcoma, leiomyosarcoma, morcellation, complications J Obstet Gynaecol Can 2015;37(1):68 78 This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions. They should be well documented if modified at the local level. None of these contents may be reproduced in any form without prior written permission of the SOGC. 68 JANUARY JOGC JANVIER 2015
27 SOGC/GOC TECHNICAL UPDATE Technical Update on Tissue Morcellation During Gynaecologic Surgery: Its Uses, Complications, and Risks of Unsuspected Malignancy Summary Statements The risk of an unexpected uterine sarcoma following surgery for presumed benign uterine leiomyoma is approximately 1 in 350, and the rate of leiomyosarcoma is 1 in 500. (II-2) This risk increases with age. (II-2) 2. An unexpected uterine sarcoma treated by primary surgery involving tumour disruption, including morcellation of the tumour, has the potential for intra-abdominal tumour-spread and a worse prognosis. (II-2) 3. Uterus-sparing surgery remains a safe option for patients with symptomatic leiomyomas who desire future fertility. (II-1)
28 SOGC/GOC TECHNICAL UPDATE Recommendations Technical Update on Tissue Morcellation During Gynaecologic Surgery: Its Uses, Complications, and Risks of Unsuspected Malignancy 1. Techniques for morcellation of a uterine specimen vary, and physicians should consider employing techniques that minimize specimen disruption and intra-abdominal spread. (III-C) 2. Each patient presenting with uterine leiomyoma should be assessed for the possible presence of malignancy, based on her risk factors and preoperative imaging, although the value of these is limited. (III-C) 3. Preoperative endometrial biopsy and cervical assessment to avoid morcellation of potentially detectable malignant and premalignant conditions is recommended. (II-2A) 4. Hereditary cancer syndromes that increase the risk of uterine malignancy should be considered a contraindication to uncontained uterine morcellation. (III-C)
29 SOGC/GOC TECHNICAL UPDATE Technical Update on Tissue Morcellation During Gynaecologic Surgery: Its Uses, Complications, and Risks of Unsuspected Malignancy 5. Uterine morcellation is contraindicated in women with established or suspected cancer. (II-2A) If there is a high index of suspicion of a uterine sarcoma prior to surgery, patients should be advised to proceed with a total abdominal hysterectomy, bilateral salpingectomy, and possible oophorectomy. (II-2C) A gynaecologic oncology consultation should be obtained. 6. Tissue morcellation techniques require appropriate training and experience. Safe practice initiatives surrounding morcellation technique and the use of equipment should be implemented at the local level. (II-3B) 7. Morcellation is an acceptable option for retrieval of benign
30
Evidence Supporting the Recommendations. Implementation of the Guideline. Benefits/Harms of Implementing the Guideline Recommendations
1 / 6 Surgical safety checklist in obstetrics and gynaecology Guideline Developer(s) Society of Obstetricians and Gynaecologists of Canada Date Released 2013 Jan Full Text Guideline Surgical safety checklist
More informationThe Management of Uterine Leiomyomas
SOGC CLINICAL PRACTICE GUIDELINE No. 318, February 2015 (Replaces, No. 128, May 2003) The Management of Uterine Leiomyomas This clinical practice guideline has been prepared by the Uterine Leiomyomas Working
More informationFibroid mapping. Haitham Hamoda MD FRCOG Consultant Gynaecologist, Subspecialist in Reproductive Medicine & Surgery King s College Hospital
Fibroid mapping Haitham Hamoda MD FRCOG Consultant Gynaecologist, Subspecialist in Reproductive Medicine & Surgery King s College Hospital Fibroids Common condition >70% of women by onset of menopause.
More informationMenstrual Disorders & Ambulatory Gynaecology
Menstrual Disorders & Ambulatory Gynaecology Mr. Nagui Lewis Aziz M B, CH B, FRCOG Consultant Gynaecologist The Royal Oldham Hospital 01/09/2018 Heavy menstrual bleeding (HMB ) is a common problem responsible
More informationMedical Management of Fibroids Esmya. Dr Paula Briggs Consultant in Sexual and Reproductive Health
Medical Management of Fibroids Esmya Dr Paula Briggs Consultant in Sexual and Reproductive Health Treatment options for Uterine Fibroids ESMYA Selective Uterine Artery Embolisation Fibroid ablation (hysteroscopic
More informationInvestigating HMB- an evidence based approach
BSGE Meeting: Contemporary management of heavy menstrual bleeding (HMB) in primary and secondary care: (7 th December 2018, RCOG) Investigating HMB- an evidence based approach T. Justin Clark MB ChB, MD(Hons),
More informationManagement of Uterine Myomas
Management of Uterine Myomas Deidre D. Gunn, MD Assistant Professor Division of Reproductive Endocrinology & Infertility February 16, 2018 Disclosures I have no relevant financial relationships to disclose.
More informationHeavy Menstrual Bleeding. Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist
Heavy Menstrual Bleeding Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist Why is HMB so important? 1:20 women aged 30-49 consult their GP with HMB Once referred to gynaecologist, surgical
More informationLaparoscopy for 10cm fibroid. Dr Jim Tsaltas Head of Monash Endosurgery Unit Clinical Director Melbourne IVF
Laparoscopy for 10cm fibroid Dr Jim Tsaltas Head of Monash Endosurgery Unit Clinical Director Melbourne IVF Peter Maher Pioneer in Laparoscopy Leader in Laparoscopy Teacher in laparoscopy What happened!!!!
More informationPALM-COEIN: Your AUB Counseling Guide
PALM-COEIN: Your AUB Counseling Guide 10 million+ Treat the cause, not the symptom In the U.S, more than 10 million women between the ages of 35 and 49 are affected by AUB 1 Diagnosis Cause Structural
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of laparoscopic laser myomectomy Introduction This overview has been prepared to assist
More informationModern Management of Fibroids
Modern Management of Fibroids Mr Narendra Pisal The Portland Hospital Fibroids Very common 20-40% of all women Up to 80% of black women by 50y Most fibroids are asymptomatic 50% will have significant symptoms
More informationConsent Advice No. XX (Joint with BSGE) Peer Review Draft Spring Morcellation for Laparoscopic Myomectomy or Hysterectomy
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 Consent Advice No. XX (Joint with BSGE) Peer Review Draft
More informationUterine-Sparing Treatment Options for Symptomatic Uterine Fibroids
Uterine-Sparing Treatment Options for Symptomatic Uterine Fibroids Developed in collaboration Learning Objective Upon completion, participants should be able to: Review uterine-sparing fibroid therapies
More informationCLINICAL PRESENTATION AND RADIOLOGY QUIZ QUESTION
Donald L. Renfrew, MD Radiology Associates of the Fox Valley, 333 N. Commercial Street, Suite 100, Neenah, WI 54956 2/12/2011 Radiology Quiz of the Week # 7 Page 1 CLINICAL PRESENTATION AND RADIOLOGY QUIZ
More informationENDOMETRIAL ABLATION: TRENDS AND CHALLENGES IN 2017
ENDOMETRIAL ABLATION: TRENDS AND CHALLENGES IN 2017 Philippe Laberge MD FRCSC ACGE Professor Obstetrics and Gynecology Laval University Quebec, Canada Disclosures I have used products or done clinical
More informationEndometrial Cancer Biopsy of the endometrium Evaluation of women of all ages
Endometrial Cancer Biopsy of the endometrium Evaluation of women of all ages Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Health System Ann Arbor, Michigan Cancer of the
More informationUse of Power Morcellators: Minimizing Liability, Assuring Safety? By Barbara Youngberg
EXAM INATIONS Examining the industry market trends that matter most to you February 2015 A Beecher Carlson Publication Use of Power Morcellators: Minimizing Liability, Assuring Safety? By Barbara Youngberg
More informationNot all roads point to hysterectomy: treatment options for fibroids
Not all roads point to hysterectomy: treatment options for fibroids MAUREEN KOHI, MD DEPARTMENT OF RADIOLOGY JEANNETTE LAGER, MD DEPARTMENT OF OBSTETRICS, GYNECOLOGY AND REPRODUCTIVE SCIENCES A lady, recently
More informationGynecologic Decision Making Based on Sonographic Findings
Gynecologic Decision Making Based on Sonographic Findings Mindy Goldman, MD Department of Obstetrics & Gynecology & Vickie A. Feldstein, MD Department of Radiology University of California, San Francisco
More informationimproved with an MIS approach. This clinical benefit for American women has been demonstrated with Level I evidence. Hysterectomy is one of the most
Statement of the Society of Gynecologic Oncology to the Food and Drug Administration s Obstetrics and Gynecology Medical Devices Advisory Committee Concerning Safety of Laparoscopic Power Morcellation
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal myomectomy in leiomyoma management, 77 Abnormal uterine bleeding (AUB) described, 103 105 normal menstrual bleeding vs., 104
More informationOver the past year, a few gems have been
UPDATE Abnormal uterine bleeding Howard T. Sharp, MD Dr. Sharp is Professor and Vice Chair for Clinical and Quality Activities, Department of Obstetrics and Gynecology, University of Utah Health Sciences
More informationSURGICAL PROBLEMS IN FERTILITY- FIBROIDS. Dr.Māris Arājs gyn-ob specialist Cell phone:
SURGICAL PROBLEMS IN FERTILITY- FIBROIDS Dr.Māris Arājs gyn-ob specialist maris@myclinicriga.lv Cell phone: +371 26556466 There is NO Industry Sponsorship and Financial Conflict of Interest for this presentation
More informationFibroids: diagnosis and management
Link to this article online for CPD/CME credits 1 University of Glasgow, Glasgow Royal Infirmary Campus, Glasgow G31 2ER, UK 2 University of Birmingham, Birmingham Women s Hospital, Birmingham, UK 3 The
More informationEndometrial Ablation in the Management of Abnormal Uterine Bleeding
SOGC CLINICAL PRACTICE GUIDELINE No. 322, April 2015 Endometrial Ablation in the Management of Abnormal Uterine Bleeding This clinical practice guideline has been reviewed by the Clinical Practice Gynaecology
More informationDipartimento Materno-Infantile Direttore : Paolo Puggina. Miomectomia laparoscopica indicazioni e limiti Giuseppe De Francesco
Dipartimento Materno-Infantile Direttore : Paolo Puggina Miomectomia laparoscopica indicazioni e limiti Giuseppe De Francesco The clinical dilemma is whether we treat all symptomatic uterine leiomyomas
More informationTips, Tricks & Controversies in Laparoscopic Hysterectomy. No disclosures. Keys to success. Learning Objectives
Tips, Tricks & Controversies in Laparoscopic Hysterectomy Alison Jacoby, MD Dept of Obstetrics, Gynecology and Reproductive Sciences No disclosures Learning Objectives Keys to success Incorporate new surgical
More informationCOLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS, SINGAPORE 2006
COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS, SINGAPORE 2006 CONSENSUS STATEMENT ON THE MANAGEMENT AND EVALUATION OF MENORRHAGIA (INCLUDING MANAGEMENT OF FIBROIDS) Introduction Menorrhagia is defined as
More informationFrequency of menses. Duration of menses 3 days to 7 days. Flow/amount of menses Average blood loss with menstruation is 60-80cc.
Frequency of menses 24 days (0.5%) to 35 days (0.9%) Age 25, 40% are between 25 and 28 days Age 25-35, 60% are between 25 and 28 days Teens and women over 40 s cycles may be longer apart Duration of menses
More informationMedical treatment for uterine fibroids
Medical treatment for uterine fibroids Prof Mary Ann Lumsden Prof of Gynaecology and Medical Education University of Glasgow Senior Vice President RCOG Conflict of Interest Chair, Guideline development
More informationHeavy menstrual bleeding: assessment and management
Heavy menstrual bleeding: assessment and management NICE guideline Draft for consultation, August 0 This guideline covers assessing and treating heavy menstrual bleeding. It aims to help healthcare professionals
More informationGYNECOLOGY UPDATE IN. & Minimally Invasive Surgery. 6th Annual Collaborative Symposium
Mayo Clinic School of Continuous Professional Development 6th Annual Collaborative Symposium UPDATE IN GYNECOLOGY & Minimally Invasive Surgery In collaboration with BRIGHAM AND WOMEN S HOSPITAL Florida
More informationEndometriosis. *Chocolate cyst in the ovary
Endometriosis What is endometriosis? Endometriosis is a common condition in young women. It's chronic, painful, and it often progressively gets worse over the time. *Chocolate cyst in the ovary Normally,
More informationPerimenopausal DUB. Mary Anne Jamieson, MD Associate Professor, OB/GYN Queen s University Kingston, Ontario
Perimenopausal DUB Mary Anne Jamieson, MD Associate Professor, OB/GYN Queen s University Kingston, Ontario Objectives Clinicians will: Make a confident diagnosis for Perimenopausal DUB (know how/when to
More informationNICE guideline Published: 14 March 2018 nice.org.uk/guidance/ng88
Heavy menstrual bleeding: assessment and management NICE guideline Published: 14 March 2018 nice.org.uk/guidance/ng88 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationPRE-ASS ESSMENT. Endometrial Ablation for Menorrhagia
PRE-ASS ESSMENT No. 30 Feb 2004 Before decides to undertake a health technology assessment, a pre-assessment of the literature is performed. Pre-assessments are based on a limited literature search; they
More informationAulia Rahman, S. Ked Endang Sri Wahyuni, S. Ked Nova Faradilla, S. Ked
Authors : Aulia Rahman, S. Ked Endang Sri Wahyuni, S. Ked Nova Faradilla, S. Ked Faculty of Medicine University of Riau Pekanbaru, Riau 2009 Files of DrsMed FK UR (http://www.files-of-drsmed.tk 0 INTTRODUCTION
More information2/24/19. Myometrial evaluation. Size Echotexture. Homogeneous Heterogeneous. Adenomyosis Fibroids. Adenomyosis. MUSA guidelines
Content Adenomyosis and MUSA guidelines for myometrial disorders Adenomyosis MUSA guidelines Dr Lufee Wong FRANZCOG, MPH, DDU Recommended reporting guidelines Fibroids Adenomyosis Myometrial evaluation
More informationPatient Input CADTH COMMON DRUG REVIEW. ulipristal acetate (Fibristal) (Allergan Inc.) Indication: Uterine fibroids (signs and symptoms)
CADTH COMMON DRUG REVIEW Patient Input ulipristal acetate (Fibristal) (Allergan Inc.) Indication: Uterine fibroids (signs and symptoms) CADTH received patient input for this review from: Canadian Women
More informationTissue Morcellation: Managing Risks to Drive Best Patient Outcomes
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationConflicts 10/5/2016. Abnormal Uterine Bleeding. Objectives Review diagnosis and updated nomenclature. Management options for acute and chronic AUB.
Abnormal Uterine Bleeding Barbara L. Keller, MD JD Naval Hospital Oak Harbor OB/GYN Physician Conflicts I have no conflicts or financial interests to disclose. Objectives Review diagnosis and updated nomenclature.
More information5 Mousa Al-Abbadi. Ola Al-juneidi & Obada Zalat. Ahmad Al-Tarefe
5 Mousa Al-Abbadi Ola Al-juneidi & Obada Zalat Ahmad Al-Tarefe Abnormal Uterine Bleeding (AUB) AUB is a very common scenario or symptom where women complain of menorrhagia (heavy and/or for long periods),
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Abnormal uterine bleeding in the perimenopause Perimenopausal menstrual problems are among the most common causes for family practitioner and specialist referral. Often it is due to the hormone changes
More informationpatient education Fact Sheet
patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations OCTOBER 2017 BRCA1 and BRCA2 Mutations Cancer is caused by several different factors. A few types of cancer run in families. These types are
More informationClinical Utility of PALM-COEIN Classification for Abnormal Uterine Bleeding
DOI: http://doi.org/10.4038/sljog.v39i3.7818 Clinical Utility of PALM-COEIN Classification for Abnormal Uterine Bleeding Gunasena GGA a, Jayasundara DMCS b Key words: PALM-COEIN classification system,
More informationMolly A. Brewer DVM, MD, MS Chair and Professor Department of Obstetrics and Gynecology University of Connecticut School of Medicine
Molly A. Brewer DVM, MD, MS Chair and Professor Department of Obstetrics and Gynecology University of Connecticut School of Medicine Review causes of abnormal uterine bleeding: Adolescent Reproductive
More informationProgram Schedule. Update in Gynecology and Minimally Invasive Surgery 2018
Program Schedule Update in Gynecology and Minimally Invasive Surgery 2018 Wednesday, February 7, 2018 6:00 a.m. Registration & Breakfast with Exhibitors 6:55 a.m. Welcome Announcements SESSION: Practical
More information5/5/2010 FINANCIAL DISCLOSURE. Abnormal Uterine Bleeding. Is This A Problem? About me % of visits to gynecologist
Abnormal Uterine FINANCIAL DISCLOSURE I HAVE NO FINANCIAL INTEREST IN ANY OF THE PRODUCTS MENTIONED IN MY PRESENTATION Bryan K. Rone, M.D. University of Kentucky Obstetrics and Gynecology May 5, 2010 About
More informationIn November 2014, the U.S. Food and Drug Administration
MS NO: ONG-15-1598 Current Commentary U.S. Food and Drug Administration s Guidance Regarding Morcellation of Leiomyomas Well-Intentioned, But Is It Harmful for Women? William H. Parker, MD, Andrew M. Kaunitz,
More informationCore Module 7: Surgical Procedures
Core Module 7: Surgical Procedures Learning outcomes: To understand and demonstrate appropriate knowledge, skills and attitudes in relation to surgical procedures Knowledge criteria GMP Clinical competency
More informationConsidering Surgery for Fibroids? Learn about minimally invasive da Vinci Surgery
Considering Surgery for Fibroids? Learn about minimally invasive da Vinci Surgery The Condition: Uterine Fibroid (Fibroid Tumor) A uterine fibroid is a benign (non-cancerous) tumor that grows in the uterine
More informationClinical Trials: Uterine Fibroids
Clinical Trials: Uterine Fibroids Phyllis C. Leppert, MD, PhD President, The Campion Fund Professor Emerita of Obstetrics and Gynecology Duke University School of Medicine Uterine fibroids: a connective
More informationAbnormal uterine bleeding:
Primary Care Women s Health Forum 16th June 2010 Abnormal uterine bleeding: The University Of Birmingham T Justin Clark MD (Hons), MRCOG Consultant Obstetrician and Gynaecologist Birmingham Women s Hospital
More informationSurgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk
Surgery to Reduce the Risk of Ovarian Cancer Information for Women at Increased Risk Centre for Genetics Education NSW Health 2017 The Centre for Genetics Education NSW Health Level 5 2C Herbert St St
More informationMinimal Access Surgery in Gynaecology
Gynaecology & Fertility Information for GPs August 2014 Minimal Access Surgery in Gynaecology Today, laparoscopy is an alternative technique for carrying out many operations that have traditionally required
More informationThe Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility
SOGC CLINICAL PRACTICE GUIDELINE No. 321, March 2015 The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility This clinical practice guideline was prepared by the Reproductive
More informationPREGNANCY OUTCOMES AFTER MYOMECTOMY IN INFERTILE WOMEN WITH FIBROIDS: A SYSTEMATIC REVIEW OF THE LITERATURE A THESIS SUBMITTED TO THE FACULTY OF THE
PREGNANCY OUTCOMES AFTER MYOMECTOMY IN INFERTILE WOMEN WITH FIBROIDS: A SYSTEMATIC REVIEW OF THE LITERATURE A THESIS SUBMITTED TO THE FACULTY OF THE UNIVERSITY OF MINNESOTA BY ESTHER CHINWEUCHE OKEKE IN
More informationShould We Still Be Undertaking Open Myomectomies? A Five-Year Retrospective Case Review
Volume 1 Issue 1 2016 Page 9 to 17 Research Article Gynaecology and Perinatology Should We Still Be Undertaking Open Myomectomies? A Five-Year Retrospective Case Review Ioannis Athanasios Dedes 1a *, Rachel
More informationClinical Efficacy and Complications of Uterine Artery Embolization in Symptomatic Uterine Fibroids
Global Journal of Health Science; Vol. 8, No. 7; 2016 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Clinical Efficacy and Complications of Uterine Artery Embolization
More informationProgram Schedule. Update in Gynecology and Minimally Invasive Surgery 2018
Program Schedule Update in Gynecology and Minimally Invasive Surgery 2018 Wednesday, February 7, 2018 6:00 a.m. Registration & Breakfast with Exhibitors SESSION: Anatomy, Ovarian Remnant and Modern Abdominal
More informationMEDICAL POLICY SUBJECT: ENDOMETRIAL ABLATION
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of microwave endometrial ablation Introduction This overview has been prepared to assist
More informationSubject Index. Cavaterm, endometrial ablation complications 146, 150 contraindications 152 cost analysis compared with hysterectomy
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Abnormal uterine bleeding, see also Adenomyosis, Endometrial cancer, Menorrhagia dilatation and curettage 21, 22, 25 hysteroscopy of premenopausal women anesthesia
More informationManagement of Endometrial Hyperplasia
Management of Endometrial Hyperplasia Green-top Guideline No. 67 RCOG/SGE Joint Guideline February 2016 Management of Endometrial Hyperplasia This is the first edition of this guideline.this is a joint
More informationInternational Journal of Scientific Research and Reviews
Research article Available online www.ijsrr.org ISSN: 2279 0543 International Journal of Scientific Research and Reviews Efficacy of Ulipristal Acetate In Management of Symptomatic Uterine Fibroids : A
More informationAn MRI pictorial review of uterine fibroid expulsion after uterine artery embolisation
An MRI pictorial review of uterine fibroid expulsion after uterine artery embolisation Poster No.: C-1893 Congress: ECR 2017 Type: Educational Exhibit Authors: E. Y. Auyoung, L. Ratnam, R. Das, S. Ameli-Renani,
More informationFreedom of Information
ND ref. FOI/16/309 Freedom of Information Thank you for your 19/10/16 request for the following information: Under the Freedom of Information Act, please could you fill out the following Freedom of Information
More informationJMSCR Vol 05 Issue 06 Page June 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i6.29 MRI in Clinically Suspected Uterine and
More informationUTERINE LEIOMYOSARCOMA. About Uterine leiomyosarcoma
UTERINE LEIOMYOSARCOMA Uterine Lms, Ulms Or Just Lms Rare uterine malignant tumour that arises from the smooth muscular part of the uterine wall. Diagnosis Female About Uterine leiomyosarcoma Uterine LMS
More informationUterine Morcellation: Teasing Out the Issues
Uterine Morcellation: Teasing Out the Issues Stacey A. Scheib, MD, FACOG Director, Minimally Invasive Gynecology Director, Hopkins Multidisciplinary Fibroid Center Johns Hopkins Hospital Disclosures I
More information4 Proven Ways of How To Treat Fibroids Naturally
4 Proven Ways of How To Treat Fibroids Naturally Below is an in-depth post that answers virtually each question on how to treat fibroids naturally. Get the time to browse it to the end as it is very informative.
More informationCLEAR COVERAGE HYSTERECTOMY CHECKLISTS
CLEAR COVERAGE HYSTERECTOMY CHECKLISTS Click on the link below to access the checklist sheet. Abnormal Uterine Bleeding Adenomyosis Chronic Abdominal or Pelvic Pain Endometriosis Fibroids General Guidelines
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of balloon thermal endometrial ablation (Cavaterm) Introduction This overview has been prepared
More information1/22/2016. This speaker has no conflicts of interest to disclose relative to the contents of this presentation. AAGL Spokesperson for Morcellation
The Morcellation Controversy Jubilee Brown, M.D. Professor The University of Texas M.D. Anderson Cancer Center Department of Gynecologic Oncology 30th Sanford H. Cole Symposium January 29, 2016 This speaker
More informationIMS QUIZ on Perimenopausal Bleeding, Bangalore Menopause Society marks
IMS QUIZ on Perimenopausal Bleeding, Bangalore Menopause Society 19.11.2017 100 marks Fill in the blanks 20 marks 1. Gestrinone is a synthetic derivative of 19-nortestosterone steroid nucleus 2. Risk of
More informationEndometrial Stromal Sarcoma
May 26, 2011 By Sushila Ladumor, MD [1] Endometrial stromal sarcoma (ESS) is a rare malignant tumor of the endometrium, occurring in the age group of 40-50 years. History The 50-year-old, female patient
More informationDr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre
Dr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre AUB Outline Terminology Classification/Etiology Assessment Treatment Referral to Gynaecology U c pt 4
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More informationExcessive menstrual blood loss
Ian Chilcott Excessive menstrual blood loss >80mls - That interferes with physical, emotional, social and material quality of life 1 in 20 women aged 30 to 49 years consult their GP each year with menorrhagia
More informationFibroid Tumors And Endometriosis By Susan M. Lark READ ONLINE
Fibroid Tumors And Endometriosis By Susan M. Lark READ ONLINE If you are looking for a ebook Fibroid Tumors and Endometriosis by Susan M. Lark in pdf format, in that case you come on to the faithful site.
More informationDr John Short. Obstetrician and Gynaecologist Christchurch Women s Hospital Oxford Women's Health Christchurch
Dr John Short Obstetrician and Gynaecologist Christchurch Women s Hospital Oxford Women's Health Christchurch 16:30-17:30 WS #125: Everything GPs Should Know About Gynaecologists 17:35-18:30 WS #135: Everything
More informationHealthcare Education Research
Healthcare Education Research Heavy menstrual bleeding: investigation, diagnosis & management An update for health professionals Assessment of heavy menstrual bleeding in primary care Dr Amanda Newman
More informationA survey on the histopathologic findings in 636 cases of hysterectomy: A sonographic assessment study
Available online at http://www.ijabbr.com International journal of Advanced Biological and Biomedical Research Volume 1, Issue 11, 2013: 1471-1477 A survey on the histopathologic findings in 636 cases
More informationChapter 2. Implementation of hysteroscopic surgery in The Netherlands. Heleen van Dongen Wendela Kolkman Frank Willem Jansen
Chapter 2 Implementation of hysteroscopic surgery in The Netherlands Heleen van Dongen Wendela Kolkman Frank Willem Jansen Adapted from Eur J Obstet Gynecol Reprod Biol 07;132:232-236 Introduction Diagnostic
More informationManaging infertility when adenomyosis and endometriosis co-exist
Managing infertility when adenomyosis and endometriosis co-exist Jinhua Leng Beijing,China Endometriosis Endometriosis (EM) is a common, benign, ovary hormone-dependent gynecologic disorder which affects
More informationRealizing dreams booklet.indd 1 5/20/ :26:52 AM
Realizing dreams. 18891booklet.indd 1 5/20/2010 11:26:52 AM The Journey To Parenthood The first Gator Baby was born in 1988 through the in vitro fertilization program at the University of Florida. Since
More informationIndex. B Bilateral salpingo-oophorectomy (BSO), 69
A Advanced stage endometrial cancer diagnosis, 92 lymph node metastasis, 92 multivariate analysis, 92 myometrial invasion, 92 prognostic factors FIGO stage, 94 histological grade, 94, 95 histologic cell
More informationHealth technology The use of gonadotrophin-releasing hormone agonists (GnRHa) in women with uterine fibroids, undergoing hysterectomy or myomectomy.
Cost effectiveness of pre-operative gonadotrophin releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy Farquhar C, Brown P M, Furness S Record Status This is a critical
More informationAbnormal uterine bleeding in fertile age Minimally invasive surgical solution
Abnormal uterine bleeding in fertile age Minimally invasive surgical solution Professor Grigoris F. Grimbizis Head, 1 st Dept Obstet & Gynecol, Aristotle University of Thessaloniki ESGE Chair Elect Declaration
More informationpatient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015
patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer
More informationSurgery and Infertility
Surgery and Infertility Dr Phill McChesney BHB MBChB FRANZCOG MRMed CREI Laparoscopy Prior to Considering IVF Diagnostic Tubal Surgery Treatment of peritubal adhesions Reconstructive surgery Sterilization
More informationCorrelation of Endometrial Thickness with the Histopathological Pattern of Endometrium in Postmenopausal Bleeding
DOI 10.1007/s13224-014-0627-z ORIGINAL ARTICLE Correlation of Endometrial Thickness with the Histopathological Pattern of Endometrium in Postmenopausal Bleeding Singh Pushpa Dwivedi Pooja Mendiratta Shweta
More informationPedram Bral, M.D. Maimonides Medical Center Brooklyn, New York
Pedram Bral, M.D. Maimonides Medical Center Brooklyn, New York 2-Year Program Optional Degrees: MPH MBA MS Other: None Number of Faculty: GYN Faculty: 4 UROGYN Faculty: 2 REI Faculty: 1 ONCOLOGY Faculty:
More informationGuidelines for performing gynaecological endoscopic procedures
Guidelines for performing gynaecological endoscopic procedures This statement has been developed by the Women s Health Committee. It has been reviewed by the Endoscopic Surgery Advisory Committee (RANZCOG/AGES)
More informationIntroduction to GYN Specialties
Outline Introduction to GYN Specialties Gynecologic Oncology* Female Pelvic Medicine and Reconstructive Surgery* Reproductive Endocrinology and Infertility* Pediatric and Adolescent Gynecology** Family
More informationEVALUATING THE INFERTILE PATIENT-COUPLES. Stephen Thorn, MD
EVALUATING THE INFERTILE PATIENT-COUPLES Stephen Thorn, MD Overview The field of reproductive medicine continues to evolve rapidly by offering newer diagnostic testing and therapeutic options to improve
More informationbleeding Studies naar de diagnostiek van endom triumcarcinoom bij vrouwen met postm nopauzaal bloedverlies. Studies on the
Studies on the diagnosis of endometria cancer in women with postmenopausal bleeding. Studies naar de diagnostiek va endometriumcarcinoom bij vrouwen m postmenopauzaal bloedverlies. Studies on the diagnosis
More informationEndometrial line thickness in different conditions.
Endometrial line thickness in different conditions 1 Endometrial thickens in response to Rising estrogen levels during the menstrual cycle and then shedding endometrial at the times of menses 2 The thickens
More informationCenter for Menstrual Disorders, Fibroids and Hysteroscopic Services
Center for Menstrual Disorders, Fibroids and Hysteroscopic Services If you experience heavy periods, there is no need to suffer in silence. And if you ve been told that hysterectomy is your only choice,
More information